Zentalis Pharmaceuticals, Inc. $ZNTL

What the company doesAI summary of filing

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, an investigational WEE1 inhibitor for ovarian cancer and other solid tumors. The company is focused on advancing azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, with clinical trial data showing an objective response rate over 30% in this patient population. Zentalis has no approved products or product revenue and is dependent on raising capital to fund its clinical development programs. The company exclusively licenses worldwide development and commercialization rights to azenosertib and relies on third-party contract manufacturers for drug production. [10-K 2026-03-26]

Segments: Azenosertib (WEE1 inhibitor) - monotherapy in Cyclin E1-positive PROC, Azenosertib - combination with bevacizumab in ovarian cancer, Azenosertib - monotherapy in PARP-inhibitor resistant ovarian cancer, Azenosertib - monotherapy in uterine serous carcinoma (completed, no further development planned)